New hope for Tough-to-Treat leukemia: early trial tests novel drug combo
NCT ID NCT05453903
Summary
This early-stage study is testing a new drug called bleximenib in combination with standard treatments for acute myeloid leukemia (AML) that has specific genetic changes. The main goals are to find the safest and most effective dose and to see how well patients tolerate the combination. The study will also look for early signs that the treatment is working to control the leukemia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Grande Ospedale Metropolitano Niguarda
Milan, 20162, Italy
-
Albert Einstein College Of Medicine
New York, New York, 10461, United States
-
Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna
Bologna, 40138, Italy
-
CHU de Tours - Hôpital de Bretonneau
Tours, 37044, France
-
Charite Universitaetsmedizin Berlin
Berlin, 13353, Germany
-
Christie Hospital NHS Trust
Manchester, M20 4BX, United Kingdom
-
Chu Rennes Hopital Pontchaillou
Rennes, 35033, France
-
City of Hope
Duarte, California, 91010, United States
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Hosp Clinic de Barcelona
Barcelona, 08036, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp Univ Vall D Hebron
Barcelona, 8035, Spain
-
Hosp. de La Santa Creu I Sant Pau
Barcelona, 08025, Spain
-
IRCCS Istituto Clinico Humanitas
Rozzano, 20089, Italy
-
Institut Paoli Calmettes
Marseille, 13273, France
-
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, 31100, France
-
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, 47014, Italy
-
MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Monash Medical Centre
Clayton, 3168, Australia
-
Novant Health
Charlotte, North Carolina, 28204, United States
-
Novant Health Forsyth Medical Center
Winston-Salem, North Carolina, 27103, United States
-
Oxford University Hospitals NHS Trust
Oxfordshire, OX3 7LE, United Kingdom
-
Peter MacCallum Cancer Centre
Melbourne, 3000, Australia
-
Princess Margaret Cancer Centre University Health Network
Toronto, Ontario, M5G 1Z5, Canada
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
Universitaetsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitaetsklinikum Leipzig
Leipzig, 04103, Germany
-
Universitatsklinikum Carl Gustav Carus Dresden
Dresden, 01307, Germany
-
Universitatsklinikum Ulm
Ulm, 89081, Germany
-
University College London Hospitals NHSFT
London, NW1 2PG, United Kingdom
-
Westmead Hospital
Westmead, 2145, Australia
Conditions
Explore the condition pages connected to this study.